Trial Profile
Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 05 Sep 2019 Planned initiation date changed from 1 May 2016 to 6 Aug 2016.
- 05 Sep 2019 Status has been changed to withdrawn prior to enrolment.
- 08 Feb 2017 Planned End Date changed from 1 May 2020 to 31 May 2020.